Andrew Sims - Plus Therapeutics VP CFO
| PSTV Stock | USD 1.23 0.05 4.24% |
Insider
Andrew Sims is VP CFO of Plus Therapeutics
| Age | 50 |
| Address | 4200 Marathon Boulevard, Austin, TX, United States, 78756 |
| Phone | 737 255 7194 |
| Web | https://plustherapeutics.com |
Andrew Sims Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Sims against Plus Therapeutics stock is an integral part of due diligence when investing in Plus Therapeutics. Andrew Sims insider activity provides valuable insight into whether Plus Therapeutics is net buyers or sellers over its current business cycle. Note, Plus Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Plus Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Sims over a month ago Disposition of 5692 shares by Andrew Sims of Sotherly Hotels at 6.755 subject to Rule 16b-3 | ||
Andrew Sims over two months ago Acquisition by Andrew Sims of 4098 shares of Plus Therapeutics at 1.27 subject to Rule 16b-3 | ||
Andrew Sims over three months ago Acquisition by Andrew Sims of 53971 shares of Sotherly Hotels subject to Rule 16b-3 | ||
Andrew Sims over six months ago Acquisition by Andrew Sims of 9804 shares of Plus Therapeutics at 1.79 subject to Rule 16b-3 |
Plus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6939) % which means that it has lost $0.6939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.225) %, meaning that it created substantial loss on money invested by shareholders. Plus Therapeutics' management efficiency ratios could be used to measure how well Plus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 10.37 in 2024, whereas Return On Tangible Assets are likely to drop (1.27) in 2024. Total Current Assets is likely to climb to about 17.1 M in 2024, whereas Total Assets are likely to drop slightly above 10.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Marcel CPA | Altamira Therapeutics | 66 | |
| DSc MSE | Immix Biopharma | 75 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| James Rolke | Revelation Biosciences | 55 | |
| Elizabeth Evans | Vaccinex | 51 | |
| Alexandra MD | Avenue Therapeutics | 57 | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| James Foster | Virax Biolabs Group | 39 | |
| David Briones | Hoth Therapeutics | 48 | |
| PharmD BCPS | Neurobo Pharmaceuticals | N/A | |
| Charles Williams | Surrozen | 44 | |
| Nandan BS | Immix Biopharma | 62 | |
| Christopher Garcia | Surrozen | N/A | |
| Sharon McBrayer | Palisade Bio | N/A | |
| Calvin MD | Surrozen | N/A | |
| Gerald Proehl | Dermata Therapeutics | 65 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Ben MD | Neurobo Pharmaceuticals | 68 | |
| MBA IV | Enveric Biosciences | 68 | |
| Thomas CPA | Aditxt Inc | 51 | |
| Tomasz George | Virax Biolabs Group | 40 | |
Management Performance
| Return On Equity | -5.22 | ||||
| Return On Asset | -0.69 |
Plus Therapeutics Leadership Team
Elected by the shareholders, the Plus Therapeutics' board of directors comprises two types of representatives: Plus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Plus. The board's role is to monitor Plus Therapeutics' management team and ensure that shareholders' interests are well served. Plus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Plus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, CEO President | ||
| John Fraser, Chief Scientist | ||
| Gary CPA, Advisor | ||
| MS MBA, New Strategy | ||
| Marc MD, CEO Pres | ||
| Desiree Smith, Principal Controller | ||
| Andrew Sims, VP CFO | ||
| Andrew CPA, VP CFO | ||
| FACNP FACP, Chief VP |
Plus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Plus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.22 | ||||
| Return On Asset | -0.69 | ||||
| Profit Margin | (2.40) % | ||||
| Operating Margin | (2.89) % | ||||
| Current Valuation | 5.57 M | ||||
| Shares Outstanding | 5.9 M | ||||
| Shares Owned By Insiders | 2.34 % | ||||
| Shares Owned By Institutions | 11.30 % | ||||
| Number Of Shares Shorted | 52.34 K | ||||
| Price To Book | 3.76 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.